Concordance rates of first and second breast cancer were 84.7% and 71.4% for ER, 80.4% and 68.5% for PR, and 86.9% and 62.9% for HER2 in synchronous and metachronous bilateral breast cancers, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.